In the last decade, inhibitors of the B cell receptor (BCR) and B cell lymphoma 2 (BCL2) signaling pathways have become part of the CLL therapeutic landscape, and their use has been steadily increasing thanks to higher efficacy and reduced adverse events compared to CIT [4]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.